Member of the Board of Directors and R&D/Science Chair Dr. Kim Blackwell is serving on the board of directors of Fore since September 2021. Dr. Kim Blackwell currently serves as CEO of Zentalis Pharmaceuticals. Priot to Zentalis Pharmaceuticals Dr. Kim Blackwell served as Tempus’ Chief Medical Officer. She joins Tempus from Eli Lilly, where she was Vice President of Early Phase Oncology and Immuno-oncology. Prior to that, she was a Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University, where she directed the Women’s Cancer Program, Strategic Collaborations, and the Precision Medicine Initiative for the Duke Cancer Institute.